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A Lower Dose of Efavirenz 
Can Be Coadministered With 
Rifampicin and Isoniazid in 
Tuberculosis Patients
To the Editor—The ENCORE-1 study 
demonstrated noninferiority of efavirenz 
400 mg once daily (EFV400) when com-
pared with the standard dose (EFV600) 
[1]. Based on these data, the World 
Health Organization (WHO) recom-
mends EFV400 as an alternative first-
line antiretroviral drug but restricts its 
use to nonpregnant patients and patients 
without tuberculosis (TB) [2]. However, 
a recently published study in United 
Kingdom human immunodeficiency 
virus (HIV)-positive patients without 
TB found EFV concentrations to be ade-
quate when EFV400 was coadministered 
with rifampicin and isoniazid (RH) [3]. 
To confirm these results in a TB-infected 
population, we conducted an open label, 
nonrandomized, pharmacokinetic study 
in HIV/TB coinfected patients in Uganda.
Ethics approval was obtained from 
the Joint Clinical Research Committee 
Institutional Research Board. We 
enrolled patients who were receiving 
EFV600 once daily plus lamivudine and 
tenofovir disoproxil fumarate or zidovu-
dine for at least 3 weeks in addition to 
the WHO-recommended oral doses of 
RH. Thereafter, we reduced their EFV 
dose to 400 mg but maintained doses of 
the remaining drugs in their HIV and TB 
regimens.
To ensure prompt identification of 
subtherapeutic concentrations, we con-
ducted twice-weekly therapeutic drug 
monitoring (TDM) of EFV400 mid-dose 
concentrations. A priori, the protocol 
stipulated that patients with more than 
3 low EFV levels (<800 ng/mL) would be 
withdrawn from the study and switched 
to EFV600. A threshold of 800 ng/mL 
was chosen based on the receiver oper-
ating characteristic (ROC) curve analysis 
performed in the ENCORE-1 study [4].
At 28 (±7) days of EFV400 treatment, 
intensive pharmacokinetic sampling was 
performed at 0, 2, 4, 8, 12, and 24 hours 
postdose. Afterwards, patients had their 
EFV dose restored to 600 mg. We then 
measured EFV concentrations using a 
validated reversed-phase ultraperfor-
mance liquid chromatography coupled 
with UV detection method as described 
previously [3]. Pharmacokinetic param-
eters were calculated using noncom-
partmental techniques (WinNonlin 
Phoenix, version 7.0; Pharsight Corp, 
Mountain View, CA). Results were pre-
sented as geometric means and 95% 
confidence intervals. In addition, we per-
formed genotyping of known functional 
polymorphisms linked with increased 
EFV concentrations (CYP2B6 516G>T 
[rs3745274, CYP2B6*6] and 983T>C 
[rs28399499, CYP2B6*18]) as described 
previously [3].
We enrolled 10 HIV/TB-coinfected 
patients, 5 of whom were female. The 
median age and weight were 34 (range, 
23–45) years and 54 (range, 41–65.5) 
kg, respectively. All subjects completed 
day 28 (1 missed the 24-hour pharma-
cokinetic blood draw). Median baseline 
and day 28 viral load were 38.5 (range, 
10–405 081) and 10 (range, 10–393 886) 
copies/mL, respectively.
No study subjects had to be withdrawn 
from the study before day 28 because of 
EFV TDM results below 800 ng/mL. One 
subject had EFV concentrations below 
800 ng/mL before and on day 28 and had 
to be discontinued; however, these were 
all above 470 ng/mL, the lower limit of 
the ROC curve established by Dickinson 
et al [4] in the ENCORE-1 pharmacoki-
netic substudy. Of the 10 subjects, 9 were 
genotyped. Four subjects were EFV in-
termediate metabolizers (as carriers of 2 
variant alleles at position 516 but none at 
983) and showed higher EFV concentra-
tions despite the EFV dose reduction. On 
the other hand, 5 subjects were extensive 
metabolizers with no variant allele at po-
sition 516 or 983.
Efavirenz 400 mg once daily with 
RH pharmacokinetic parameters at day 
28 are shown in Table 1. Overall, target 
EFV concentrations were achieved in 
TB-HIV-coinfected patients receiving 
EFV400 once daily when coadministered 
with RH, with EFV trough concentra-
tions maintained above those measured 
by Cerrone et al [3] when EFV400 was 
coadministered with RH in people living 
with HIV but not TB.
CONCLUSIONS
This study provides the first clinical 
data on the use of EFV400 in HIV-TB-
coinfected patients and adds further sup-
port for the coadministration of EFV400 
with RH in HIV/TB-coinfected patients. 
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Table 1. EFV PK Parameters During Coadministration With Rifampicin and Isoniazid in People Living With HIV and Coinfected With Tuberculosis in 
Uganda (n &#x003D; 10)
PK Parameter Cmax (ng/mL) C24h (ng/mL) AUC (ng × h/mL)
Geometric mean, 95% confidence intervals 2814 (1714–4620) 1806 (982–3321) 50269 (26520–95287)
Coefficient of variation 69% 75% 75%
Abbreviations: AUC, area under the curve; Cmax, maximum concentration; C24h, 24 hours postdose concentration; EFV, efavirenz; HIV, human immunodeficiency virus; PK, pharmacokinetic.
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Results from this study should be vali-
dated in a larger cohort.
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